Harms Results Harms results are based on the in-trial observation period with a data cut-off date of July 18, 2023
In accordance with the findings of a retrospective observational study, both sodium-glucose cotransporter-2 (SGLT2) inhibitors and the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide can help stabilize kidney function in patients with early diabetic nephropathy, though their benefits appear to differ
Available at: Accessed 7/1/19
It can support fat metabolism and improve workout energy, which may help overcome stalled progress
As a personal trainer and nutrition coach, I have worked with dozens of clients over the past couple of years who have turned to GLP-1s as a tool to assist them in their goals
In this article, "best" means products with high public visibility, consumer interest, and transparent information from public data